Randomized phase III trial of cisplatin + TS-1 [S 1] versus cisplatin + docetaxel regimens for stage IIIB/IV non-small cell lung carcinoma.

Trial Profile

Randomized phase III trial of cisplatin + TS-1 [S 1] versus cisplatin + docetaxel regimens for stage IIIB/IV non-small cell lung carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CATS
  • Most Recent Events

    • 02 Oct 2012 Final analysis presented at the 37th Congress of the European Society for Medical Oncology.
    • 06 Jun 2012 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2012 Results were reported at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), and in a Taiho Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top